glp-1 agonist. Comparing Ozempic, Wegovy and Other Drugs Clinical Focus on GLP-1 Agonists

Arguments for Game Changer Status Several compelling arguments support the characterization of GLP-1 agonists as transformative therapies: Unprecedented Efficacy : Tirzepatide marks a new era in overweight/obesity treatment, enabling many to achieve 20% weight loss [76] [77]

Liraglutide , marketed under the brand name Saxenda, is one such treatment approved for chronic weight management in individuals with a body mass index (BMI) of 30 or higher, or those with a BMI of 27 or higher who have at least one weight-related condition

Their evaluation of the effect of GLP-1 was also aided by their access to RIAs for GLP-1 (Holst 2024)

Why are investors betting on combination therapies like CagriSema over single-drug approaches

Excess abdominal fat is associated with higher inflammation and increased risk of insulin resistance, high blood pressure, and cardiovascular disease, which is why many menopausal women consider GLP-1 medications as part of a broader, clinician-guided weight management plan